DK2173381T3 - Fc-receptor bindende polypeptider med modificerede effektorfunktioner - Google Patents

Fc-receptor bindende polypeptider med modificerede effektorfunktioner

Info

Publication number
DK2173381T3
DK2173381T3 DK08872467.9T DK08872467T DK2173381T3 DK 2173381 T3 DK2173381 T3 DK 2173381T3 DK 08872467 T DK08872467 T DK 08872467T DK 2173381 T3 DK2173381 T3 DK 2173381T3
Authority
DK
Denmark
Prior art keywords
receptor binding
effector functions
binding polypeptides
modified effector
modified
Prior art date
Application number
DK08872467.9T
Other languages
English (en)
Inventor
Greg Elson
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Application granted granted Critical
Publication of DK2173381T3 publication Critical patent/DK2173381T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK08872467.9T 2007-05-14 2008-05-14 Fc-receptor bindende polypeptider med modificerede effektorfunktioner DK2173381T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93027607P 2007-05-14 2007-05-14
PCT/IB2008/003978 WO2009101479A2 (en) 2007-05-14 2008-05-14 Fc receptor-binding polypeptides with modified effector functions

Publications (1)

Publication Number Publication Date
DK2173381T3 true DK2173381T3 (da) 2013-12-02

Family

ID=40957323

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08872467.9T DK2173381T3 (da) 2007-05-14 2008-05-14 Fc-receptor bindende polypeptider med modificerede effektorfunktioner

Country Status (14)

Country Link
US (3) US8546539B2 (da)
EP (1) EP2173381B1 (da)
JP (6) JP2010526868A (da)
CN (1) CN101720232B (da)
AU (1) AU2008350535B2 (da)
CA (1) CA2689680C (da)
DK (1) DK2173381T3 (da)
ES (1) ES2441189T3 (da)
IL (1) IL202107A (da)
MX (1) MX2009012319A (da)
PL (1) PL2173381T3 (da)
PT (1) PT2173381E (da)
SI (1) SI2173381T1 (da)
WO (1) WO2009101479A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009101479A2 (en) * 2007-05-14 2009-08-20 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
US8734790B2 (en) 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
US9688769B2 (en) * 2013-10-22 2017-06-27 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
CA2932787A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
JP2018523827A (ja) * 2015-08-06 2018-08-23 ノビミューン エスアー Ｔｌｒ４依存性障害の診断および処置のための患者集団を特定するための方法および組成物
EP3601333A4 (en) * 2017-03-28 2021-05-26 Lyvgen Biopharma Holdings Limited THERAPEUTICS AND METHODS TO INCREASE IMMUNE RESPONSES IN THE TUMOR MICROENVIRONMENT
AU2018346264A1 (en) * 2017-10-03 2020-04-23 Merck Patent Gmbh Cysteine engineered antigen-binding molecules
KR20220005568A (ko) * 2019-05-09 2022-01-13 제넨테크, 인크. 항체의 제조 방법
AU2021208630A1 (en) * 2020-01-17 2022-07-21 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
AU2021261060A1 (en) * 2020-04-20 2022-11-17 Edesa Biotech Research Inc. Compositions and methods for treatment of Acute Respiratory Distress Syndrome
WO2022047125A1 (en) * 2020-08-28 2022-03-03 Board Of Regents, The University Of Texas System Antibodies specific to ccl21 and methods of use
WO2024040115A2 (en) * 2022-08-16 2024-02-22 University Of Vermont And State Agricultural College ANTIBODIES FOR PLATELET FCγRIIA AND RELATED METHODS OF USE
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US993904A (en) 1911-02-28 1911-05-30 Ribbon Metals Syndicate Ltd Apparatus for making metal strips, foil, sheets, or ribbons.
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994028025A1 (en) 1993-05-28 1994-12-08 The Scripps Research Institute Methods and compositions for inhibiting cd14 mediated cell activation
EP1746107B1 (en) 1998-04-02 2014-12-17 Genentech, Inc. Antibody variants and fragments thereof
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
WO2005028509A1 (en) 2003-09-23 2005-03-31 Technische Universitaet Muenchen Tlr2 antagonistic antibody and use thereof
AU2004311541B2 (en) 2003-12-10 2011-06-30 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2007024249A2 (en) * 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
DK1830881T3 (da) 2004-12-10 2010-09-20 Novimmune Sa Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
WO2009101479A2 (en) * 2007-05-14 2009-08-20 Novimmune Sa Fc receptor-binding polypeptides with modified effector functions
US8734790B2 (en) * 2011-01-10 2014-05-27 Novimmune Sa Anti-TLR4 antibodies and methods of use thereof
HUE037613T2 (hu) * 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása

Also Published As

Publication number Publication date
CN101720232A (zh) 2010-06-02
US20140038287A1 (en) 2014-02-06
JP2020111613A (ja) 2020-07-27
AU2008350535A1 (en) 2009-08-20
US9688755B2 (en) 2017-06-27
US8546539B2 (en) 2013-10-01
JP2014005306A (ja) 2014-01-16
WO2009101479A3 (en) 2010-02-25
JP2010526868A (ja) 2010-08-05
SI2173381T1 (sl) 2014-01-31
AU2008350535B2 (en) 2013-08-22
JP2015017133A (ja) 2015-01-29
JP2017036333A (ja) 2017-02-16
JP2018087234A (ja) 2018-06-07
PL2173381T3 (pl) 2014-03-31
CA2689680C (en) 2017-11-07
US20120142098A1 (en) 2012-06-07
CA2689680A1 (en) 2009-08-20
WO2009101479A2 (en) 2009-08-20
MX2009012319A (es) 2010-03-01
IL202107A0 (en) 2011-08-01
EP2173381B1 (en) 2013-10-02
EP2173381A2 (en) 2010-04-14
JP6360128B2 (ja) 2018-07-18
CN101720232B (zh) 2013-07-10
ES2441189T3 (es) 2014-02-03
IL202107A (en) 2014-05-28
PT2173381E (pt) 2013-12-13
US20170298129A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
DK2173381T3 (da) Fc-receptor bindende polypeptider med modificerede effektorfunktioner
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2171053T3 (da) Natriuretiske polypeptider
DK3118221T3 (da) Proteiner
DK2035447T3 (da) Polypeptid
DK2046826T3 (da) Exendin-fusionsproteiner
DK3339445T3 (da) Interleukin -13 bindende proteiner
DK2176504T3 (da) Multifunktionelt brøndeftersynsapparat
GB0721686D0 (en) Polypeptides
ATE525624T1 (de) Betätigungselement
BRPI0814971A2 (pt) Proteína
SE0850135L (sv) Häftapparat
EP2230300A4 (en) POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
GB0708376D0 (en) Novel polypeptides and uses thereof
FI20070241A0 (fi) Monitoiminen jäänmurtaja
DE502007007044D1 (de) tsmaschinen mit Nebenstromkonfiguration
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
DE602008003253D1 (de) Schiebeelement
DE602008002004D1 (de) Aktuatoranordnung
ES2569360T8 (es) Proteínas de fusión de ácaros
FI20075777A (fi) Kate-elementti
FR2913480B1 (fr) Joint tournant
BRPI0914557A2 (pt) proteína de ligação de biotina modificada
ES1063767Y (es) Bolsa multifuncional
GB0712302D0 (en) Chrondroitinase polypeptides